A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose escalation study to evaluate the safety, tolerability,
pharmacokinetics, efficacy and preliminary food effect of BB3008 as monotherapy in subjects
with advanced solid tumors.